+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

Global Request for Proposals – Pfizer Clostridioides difficile (C. difficile) Research Collaboration

Pfizer

This Request for Proposals (RFP) seeks to identify investigators with innovative research proposals who are interested in partnering with Pfizer and potentially other likeminded investigators on co-developing research studies focused on understanding the burden of Clostridioides difficile (C. difficile) infections in humans. Researchers selected from this RFP will work in collaboration with the Pfizer medical team to co-develop a research project, study protocol, and publication in peer-reviewed medical literature. In all selected studies the investigator will serve as the principle investigator and the regulatory sponsor of the study.

Geographic Scope

France, Germany, Japan, United Kingdom, United States

Key Milestones

Application submission deadline: 11 December 2025

Anticipated decision notification date: February 2026

Anticipated project start date: 1 April 2026

Funding Range and Project Length

Individual projects requesting up to $500,000 USD will be considered. Maximum project length is 12 months

AI Based Application Success Predictor

Predictor	Why It Matters	Evidence / Typical Pattern
Strong alignment with Pfizer’s therapeutic priorities	Pfizer funds research in areas directly linked to its portfolio (oncology, vaccines, inflammation, rare disease, immunology, internal medicine, cardiology).	Projects matching open RFP focus areas (e.g., breast cancer, COVID-19, IBD, hemophilia) have much higher success rates.
Scientific quality and rigor	Reviewers prioritize hypotheses with strong rationale, robust design, and measurable endpoints.	Funded IIRs include detailed protocols, power analyses, and statistical plans.
Feasibility and investigator capability	Applicants must demonstrate ability to deliver — through experience, facilities, and institutional support.	Past awardees often have prior industry collaborations or clinical trial experience.
Innovation and potential for impact	Pfizer favors novel concepts that could advance standard of care, generate real-world evidence, or improve patient outcomes.	“Innovative, practice-changing” is a core review criterion in Pfizer GMG guidelines.
Patient-centered outcomes and real-world relevance	Research must show how findings will improve clinical practice, patient experience, or access to care.	RWE (real-world evidence) and implementation science projects score highly.
Ethical and regulatory compliance	Proposals must follow ethical standards, IRB review, and independent data control.	Transparency and compliance are non-negotiable; weak governance leads to disqualification.
Interdisciplinary collaboration	Pfizer encourages academic, clinical, and community partnerships to ensure broad impact.	Multi-institutional or multidisciplinary proposals are more competitive.
Clear dissemination plan	Pfizer seeks measurable deliverables — peer-reviewed publications, conference presentations, or practice guidelines.	Reviewers favor well-defined post-grant dissemination timelines.

⚠️ Common Weaknesses in Unsuccessful Applications

Weak or indirect connection to Pfizer’s active RFP topic or disease area

Lack of innovation or incremental proposals duplicating existing data

Overly ambitious scope with limited timeline or budget

Insufficient methodological detail (missing endpoints, unclear sample size)

No clear path to clinical application or educational outcome

Incomplete documentation (missing budgets, institutional letters, compliance info)

📊 Funding & Success Rate Insights

Pfizer Global Medical Grants: success rate ≈ 10–15%, depending on competition and RFP topic.

IIR Grants: ~15–20% for experienced investigators with strong institutional support.

Education Grants (IGLC): 20–25%, depending on geographic region and therapeutic focus.

✅ Summary: Strongest Predictors of Success

Alignment with Pfizer’s defined therapeutic priorities

Strong study design and feasibility

Innovative and practice-changing potential

Patient-centered, measurable outcomes

Experienced investigator and supportive research environment

Specialties

Pharmaceuticals

Eligibility Requirements

The institution and Principal Investigator (PI) must be based in one of the eligible countries.

• Only organizations are eligible to receive funds and in-kind support, not individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society).

• If the project involves multiple departments within an institution and/or between different institutions / organizations / associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.

• The PI must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work.

• The applicant must be the PI or an authorized designee of such individual (e.g., PI’s research coordinator).

• The PI must be an employee or contractor of the requesting organization.

• If selected, the PI and their organization are willing and able to engage in a Research Collaboration with Pfizer; see definition of ‘Research Collaboration’ further down for details.

• For all Research Collaborations (RCs), the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the initiative supported by the RC, including compliance with any regulatory requirements. Pfizer may be involved in the design of the study protocol and project development, as well as the conduct or monitoring of the research program. Preference will be given to PIs that are open to collaborative agreements with other institutions with similar research interests.

• Requesting organization must be legally able to receive award funding directly from Pfizer Inc. We strongly recommend that applicants confirm this with their organization or institution prior to submitting an application. Funding awarded to organizations that are subsequently found to be unable to accept funding directly from Pfizer Inc. may be cancelled.

Eligible Countries:

France

Germany

Japan

United Kingdom

United States

Sponsor Details

Sponsor Institute/Organizations: Pfizer

Sponsor Type: Corporate/Non-Profit

Address: 66 Hudson Boulevard East New York, NY 10001-2192 USA

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity